SIA "magnipharma",

SIA "magnipharma" is a Latvian limited liability company (SIA) specializing in the wholesale distribution of pharmaceutical products. Established on December 9, 2004, the company is registered under the number 50003715491. Its legal address is Meistaru iela 8 – 7, Rīga, LV-1050, Latvia. (company.lursoft.lv) The company is owned by a single individual, Aleksandrs Kazačkovs, who also serves as a member of the board. SIA "magnipharma" plays a significant role in Latvia's pharmaceutical distribution network, acting as a primary wholesaler that imports and distributes a range of pharmaceutical products to various healthcare providers across the country.

SIA "magnipharma" operates its distribution network from its headquarters located at Meistaru iela 8 – 7, Rīga, LV-1050, Latvia. (company.lursoft.lv) While specific details about additional warehouse locations and logistics capabilities are not publicly disclosed, the company's central location in Rīga suggests a strategic position for nationwide distribution. The company is likely to utilize Latvia's well-developed transportation infrastructure, including road, rail, and port facilities, to facilitate the import and distribution of pharmaceutical products both within Latvia and potentially to neighboring countries.

In Latvia's pharmaceutical supply chain, SIA "magnipharma" functions primarily as a wholesaler. The company imports pharmaceutical products from international suppliers, including India, and distributes them to various healthcare entities such as hospitals, pharmacies, and clinics across Latvia. This role is crucial in ensuring the availability of a diverse range of pharmaceutical products to meet the healthcare needs of the Latvian population.

SIA "magnipharma" demonstrates a high level of supplier concentration, sourcing its pharmaceutical imports exclusively from EURO LIFECARE PRIVATE LIMITED, an Indian supplier. This single-source dependency indicates a strategic choice to maintain a focused and potentially more manageable supplier relationship. The company's import data reveals a consistent pattern of shipments, suggesting a stable and reliable partnership with EURO LIFECARE PRIVATE LIMITED. However, this concentration also exposes SIA "magnipharma" to risks associated with supply chain disruptions, such as those arising from geopolitical tensions, regulatory changes, or operational issues within the supplier's operations.

The resilience of SIA "magnipharma"'s supply chain is closely tied to its exclusive relationship with EURO LIFECARE PRIVATE LIMITED. While this focused sourcing strategy may streamline operations, it also means that the company has limited backup suppliers to mitigate potential disruptions. The import data indicates a narrow product range, with only two products imported from a single supplier, which could be a strategic decision to ensure quality and consistency. However, this lack of diversification may pose challenges in the event of supply chain disruptions. Additionally, the company must ensure that its supplier complies with international Good Manufacturing Practice (GMP) standards to maintain product quality and regulatory compliance.

SIA "magnipharma"'s sourcing pattern, characterized by exclusive reliance on a single supplier for a limited product range, positions the company to benefit from streamlined operations and potentially stronger supplier relationships. This focus may allow for better negotiation terms and more efficient logistics. However, the lack of supplier diversification introduces risks related to supply chain disruptions, which could impact the company's ability to meet market demand. For Indian exporters, this presents an opportunity to become alternative suppliers to SIA "magnipharma", provided they can meet the company's quality standards and regulatory requirements.

In Latvia, the State Agency of Medicines (Zāļu valsts aģentūra) is the primary regulatory authority overseeing the pharmaceutical sector. The agency is responsible for the registration, import, and distribution of medicinal products within Latvia. Key legislation governing pharmaceutical imports includes the Law on Licensing Procedures for Pharmaceutical Activities, which outlines the requirements for obtaining licenses for the import and distribution of medicinal products. The marketing authorization pathway for Indian generics involves submitting an application to the State Agency of Medicines, accompanied by necessary documentation such as a description of the manufacturing process, therapeutic indications, and results of pharmaceutical and clinical trials.

To import pharmaceutical products into Latvia, companies must obtain an import license from the State Agency of Medicines. This license authorizes the holder to import specific medicinal products into the country. Additionally, the imported products must comply with Good Manufacturing Practice (GMP) standards recognized by the European Union, WHO, or PIC/S. SIA "magnipharma" holds a wholesale distribution authorization, allowing it to distribute imported pharmaceutical products within Latvia.

Imported pharmaceutical products must undergo batch testing to ensure they meet the required quality standards. Stability studies are conducted to determine the shelf life and storage conditions of the products. Labeling requirements include providing information in the Latvian language, ensuring that patients and healthcare providers can understand the product's usage, dosage, and potential side effects. Serialization mandates may apply to track and trace the products throughout the supply chain, enhancing safety and preventing counterfeit products from entering the market.

Between 2024 and 2026, Latvia has implemented several policy changes affecting pharmaceutical imports. These include stricter compliance requirements for GMP standards, enhanced scrutiny of import licenses, and updated labeling regulations to improve patient safety and product traceability. Additionally, there have been changes in the marketing authorization process, aiming to streamline procedures and reduce approval times for new medicinal products. These regulatory updates are designed to align Latvia's pharmaceutical sector with EU standards and improve the overall quality and safety of imported medicines.

SIA "magnipharma" focuses its product strategy on antiviral and HIV medications, specifically importing Sofosbuvir and Velpatasvir. This focus aligns with the global demand for effective treatments for hepatitis C and HIV, reflecting a strategic decision to address significant public health needs. The company's import data indicates a balanced investment in these products, with each accounting for $150K in imports, suggesting a commitment to providing comprehensive antiviral therapies to the Latvian market.

SIA "magnipharma" employs a sourcing strategy that emphasizes the import of generic antiviral medications, particularly Sofosbuvir and Velpatasvir, from India. This approach allows the company to offer cost-effective treatment options while maintaining a focus on quality. The limited number of formulations imported suggests a streamlined procurement process, potentially reducing operational complexities. India's established pharmaceutical manufacturing capabilities and adherence to international GMP standards make it a suitable partner for SIA "magnipharma"'s sourcing needs.

Based on its product mix, SIA "magnipharma" serves the wholesale distribution segment of the Latvian pharmaceutical market. By importing and distributing antiviral and HIV medications, the company supplies hospitals, clinics, and pharmacies with essential treatments, thereby playing a crucial role in the healthcare supply chain. Its focus on high-demand therapeutic areas positions it as a key player in meeting the needs of healthcare providers and patients in Latvia.

There is a realistic opportunity for new Indian suppliers to enter the Latvian market by partnering with SIA "magnipharma". The company's current sourcing strategy, which relies on a single supplier for a limited product range, indicates potential gaps that new suppliers could fill. To capitalize on this opportunity, Indian exporters should ensure compliance with EU GMP standards, obtain the necessary import licenses, and meet the labeling and quality requirements set by Latvian authorities.

Indian exporters seeking to supply SIA "magnipharma" and enter the Latvian market must obtain an import license from the State Agency of Medicines. This requires submitting an application with detailed product information, including manufacturing descriptions and clinical trial results. Products must comply with EU GMP standards, and labeling must be in the Latvian language, providing clear information on usage, dosage, and potential side effects. Additionally, serialization may be required to enhance product traceability and prevent counterfeiting.

Indian exporters should initiate the relationship with SIA "magnipharma" by demonstrating compliance with EU GMP standards and providing comprehensive product documentation. Participating in Latvian pharmaceutical tenders can enhance visibility and credibility. A clear regulatory filing strategy, including obtaining the necessary import licenses and ensuring adherence to labeling and quality requirements, is essential. Timelines for approval can vary, so proactive engagement with Latvian regulatory authorities and SIA "magnipharma" is recommended to facilitate a smooth market entry.